The effective switch from intensive insulin therapy to the once-daily human GLP-1 analogue liraglutide in patients with fairly well controlled type 2 diabetes

The effective switch from intensive insulin therapy to the once-daily human GLP-1 analogue liraglutide in patients with fairly well controlled type 2 diabetes - The effective switch from intensive insulin therapy to the once-daily human GLP-1 analogue liraglutide in patients with fairly well controlled type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005202

Enrollment

Registered

2011-03-08

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Intensive insulin therapy administered by fourth-daily insulin injections was discontinued and we changed it for treatment in liraglutide alone and gradually increased clinical dosage according to the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria were adequate endogenous insulin secretion (urinary C-peptide > 40 microgram/day) and controlled HbA1c levels of <= 7.5% on intensive insulin therapy with insulin dose of < 30 units.

Exclusion criteria

Exclusion criteria: 1, Subjects who have already been treated with oral hypoglycemic agents. 2, Subjects who are hypersensitive to this medicine and/or contaminants of this medicine. 3, Any condition that the investigator considers a potential obstacle to trial participation

Design outcomes

Primary

Measure	Time frame
Changes in the parameters related to glucose profile of the subjects and proinsulin to C-peptide ratio before and after switching	—

Secondary

Measure	Time frame
Diabetes treatment satisfaction questionnaire (DTSQ), Frequency of side effects (digestive symptoms, hypoglycemia)	—

Countries

Japan

Contacts

Public ContactTaisuke Kikuchi

Kanto Rosai Hospital Department of Diabetes and Endocrinology

taisukekikuchi@kantoh.rofuku.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026